H3N2) and one influenza B virus,³ and has previously been used in children in the USA.

A 2-year-old child presented with respiratory symptoms. PCR assay of nasopharyngeal swab was strongly positive for Rhinovirus (Cycle Threshold, CT 21) and weakly positive for Influenza B (CT 37.6). Further questioning revealed that the child had received the intranasal influenza vaccine 10 days previously. Due to the difference in CT values and detection of an alternative virus (Rhinovirus), a diagnosis of Rhinovirus bronchiolitis was made and the weak Influenza B positivity was attributed to the intranasal vaccine.

Immunocompetent children vaccinated with LAIV can shed vaccine viruses for up to 3 weeks (mean duration: 7.6 days); maximal shedding occurs within 2 days of vaccination. Shedding is in lower amounts than with wild-type influenza viruses. Rarely, shed vaccine viruses can be transmitted from vaccine recipients to unvaccinated persons; however, serious illness has not been reported.⁴

Both wild-type and live-attenuated vaccine virus strains are detected by laboratory respiratory PCR assay. Wild-type and vaccine virus strains could be distinguished by genome sequencing; however, the low copy number of shed vaccine virus precludes this approach. In this case, a clinical decision must be made as to whether the influenza virus is the cause of disease or a consequence of vaccination. This will influence decisions about treating with antivirals.

As LAIV is introduced into UK clinical practice, this is a useful reminder to take care in interpreting respiratory PCR results in recently vaccinated children, highlighting the need for a precise vaccination history.

S Lumley, C Atkinson, T Haque

UCL Department of Virology, Royal Free London NHS Foundation Trust, London, UK

Correspondence to Dr S Lumley, UCL Department of Virology, Royal Free London NHS Foundation Trust, Pond Street, London NW3 2QG, UK; sheila.lumley@nhs.net

Contributors SL and CA prepared the manuscript and TH reviewed.

Competing interests None.

Provenance and peer review Not commissioned; internally peer reviewed.

OPEN ACCESS

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/3.0/>

To cite Lumley S, Atkinson C, Haque T. *Arch Dis Child* Published Online First: [please include Day Month Year] doi:10.1136/archdischild-2013-305511

Accepted 30 October 2013

Published Online First 22 November 2013

Arch Dis Child 2014;**99**:301.

doi:10.1136/archdischild-2013-305511

REFERENCES

- 1 Immunisation against infectious disease. PHE: September 2013. Chapter 19: Influenza. <https://www.gov.uk/government/publications/influenza-the-green-book-chapter-19> (accessed 28 Oct 2013).
- 2 Thors V, Smith C, Finn A. Should all children be immunised against influenza? *Arch Dis Child* 2013;**98**:846–9.
- 3 Fluenz Summary of Product Characteristics. August 2013. <http://www.medicines.org.uk/emc/medicine/25084#COMPOSITION> (accessed 28 Oct 2013).
- 4 Influenza Division, National Center for Immunization and Respiratory Diseases, CDC. Prevention and control of seasonal influenza with vaccines. *MMWR Recomm Rep* 2013;**62**(RR-07):1–43. <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6207a1.htm> (accessed 28 Oct 2013).

Respiratory PCR detects influenza after intranasal live-attenuated influenza vaccination

From 2013 an annual nasal live-attenuated influenza vaccine (LAIV—Fluenz) is available for all children in the UK aged 2 and 3 years and other ‘at-risk’ children, as part of the National Health Service (NHS) childhood vaccination programme.^{1 2} The vaccine contains reassortant influenza viruses; two influenza A viruses (H1N1 and